Business Wire

Cheetah Digital Debuts Next Generation Personalization Solution at Signals 2020

10.11.2020 20:00:00 EET | Business Wire | Press release

Share

Cheetah Digital, a cross-channel customer engagement solution provider for the modern marketer, today announces Cheetah Personalization at Signals 2020. This next-generation personalization solution is the newest addition to the Cheetah Customer Engagement Suite that includes the Cheetah Engagement Data Platform, Experiences, Messaging, and Loyalty. Cheetah Personalization helps marketers orchestrate real-time interactions across all channels and touchpoints.

To remain competitive in today’s signal-saturated world, marketers need to deliver relevant, personalized content throughout the customer journey. Ninety-one percent of consumers are more likely to shop with brands who recognize, remember, and provide relevant offers and recommendations. Furthermore, real-time offers and content can be 10 times more effective than traditional outbound marketing campaigns.

“Personalization is in the fabric of everything marketers do. But as a strategy, technology and a market, personalization is ripe for reinvention,” said Sameer Kazi, CEO at Cheetah Digital. “We wanted to create a technology blueprint for brands to achieve personalization success. With Cheetah Digital, the next-generation of personalization is here. It’s the way forward for marketers to achieve their personalization, and ultimately business, goals.”

Organizations need technology to orchestrate each aspect of personalization, from data to distribution, in order to unlock the full power of personalization. With cookies and third-party data no longer being viable options for marketers, first and zero-party data are at the core of next-generation personalization.

Cheetah Personalization leverages analytics and machine learning to evaluate every customer on an individual level to derive the right content, offer, channel and sequence for a customer journey. The new solution includes delivering the next-best experience, next-best journey and next-best offers. These capabilities are enabled by three key product offerings:

  • Cheetah Real-Time Personalization: Allows you to engage with customers in real-time with targeted experiences by capturing streaming data on web and mobile.
  • Cheetah Journey Designer: Gives marketers the power to build, manage and optimize multi-step, multi-stage customer journeys at scale.
  • Cheetah Intelligent Offers: Applies marketing insights and machine learning to optimize experiences and generate the next best offer and next best action.

“Personalization is one of the most critical themes for our customers and organization,” said Bill Ingram, Chief Product Officer at Cheetah Digital. “It’s not about guesswork, cookies or third-party data. The next generation of personalization is about providing a value exchange for consumers in the “moment” when you have them on your mobile app, on your site, in your store, where you can provide them something that will generate trust and affinity with the brand. With the data foundation of the Engagement Data Platform, we are well equipped to deliver a first class, next-generation personalization solution.”

“We were tasked with making better use of our data for more effective personalization for our guests in the face of a rapidly changing landscape,” said Katie Rhine, Corporate Marketing Manager at SeaWorld. “With Cheetah Digital’s solution, we were able to leverage zero-party data from email and deliver a more relevant and personalized experience for our guests. Now, we can personalize experiences at scale and create loyal customers across all our locations.”

This follows Cheetah Digital’s recent recognition in the MarTech Breakthrough Awards, where it was named Best Enterprise CRM Solution. To learn more about these updates and the new Cheetah Personalization solution, visit cheetahdigital.com/solutions/cheetah-personalization.

About Cheetah Digital

Cheetah Digital is a cross-channel customer engagement solution provider for the modern marketer. The Cheetah Digital Customer Engagement Suite enables marketers to create personalized experiences, cross-channel messaging, and loyalty strategies, underpinned by an engagement data platform that can scale to meet the changing demands of today's consumer. Many of the world’s best brands, including Hilton, Neiman Marcus, Walgreens, and Williams-Sonoma trust Cheetah Digital to help them drive revenue, build lasting customer relationships, and deliver a unique value exchange throughout the customer lifecycle. To learn more, visit www.cheetahdigital.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

BLASTmedia for Cheetah Digital
cheetahdigital@blastmedia.com
317-806-1900

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye